Comparison of Amyloid in Cerebrospinal Fluid, Brain Imaging, and Autopsy in a Case of Progressive Supranuclear Palsy.
Alzheimer Dis Assoc Disord
; 34(3): 275-277, 2020.
Article
en En
| MEDLINE
| ID: mdl-32520735
ABSTRACT
Cerebrospinal fluid (CSF) amyloid-beta 1-42 (Aß1-42) and amyloid positron emission tomography (PET) are the 2 main Alzheimer disease amyloid biomarkers that have been validated in neuropathologically confirmed Alzheimer disease cases. Although many studies have shown concordance of amyloid positivity or negativity between CSF Aß1-42 and amyloid PET, several studies also reported discrepancies between these 2 Aß biomarkers. We conducted a comparison of CSF Aß1-42 level, amyloid PET, and autopsy findings in a case with progressive supranuclear palsy in which biomarker acquisition and postmortem pathologic examination were conducted almost at the same time. Our case with antemortem CSF Aß1-42 (+)/amyloid PET (-) who was pathologically confirmed with Aß pathology in the cerebral cortex may indicate CSF Aß1-42 is more sensitive for assessing in vivo Aß than amyloid PET.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Fragmentos de Péptidos
/
Autopsia
/
Parálisis Supranuclear Progresiva
/
Biomarcadores
/
Péptidos beta-Amiloides
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Alzheimer Dis Assoc Disord
Asunto de la revista:
NEUROLOGIA
/
PSIQUIATRIA
Año:
2020
Tipo del documento:
Article